CJC DAC

CJC-1295 DAC – a peptide with prolonged action on the GH axis

CJC-1295 DAC (Drug Affinity Complex) is a modified version of the CJC-1295 peptide, conjugated to a molecule that binds plasma albumin. This modification significantly increases the half-life of the peptide in the research environment, which is a valuable tool in long-term experimental protocols in animal models. Substance intended for research use only (Research Use Only). Browse available CJC-1295 DAC variants from One Peptides or learn more about this peptide below.

What is CJC-1295 DAC?

CJC-1295 DAC is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue combined with the DAC (Drug Affinity Complex) module – a reactive maleimide ester that, when injected into an animal model, forms a covalent bond with plasma albumin. Thanks to this combination, the molecular weight of the entire complex increases, which effectively protects the peptide against rapid enzymatic degradation and renal elimination.

The DAC concept was developed by Montreal-based ConjuChem Biotechnologies as a way to extend the bioavailability of short-lived peptides. In the case of CJC-1295 DAC, the half-life in the plasma of animal models increases from several minutes (native CJC-1295) to several days – which is a fundamental difference in the design of research protocols.

At the molecular level, CJC-1295 DAC retains the ability to bind to the GHRH-R receptor on pituitary somatotropes. However, unlike the non-DAC version, the stimulation is not pulsatile – instead, it generates long-lasting, steady increases in GH and IGF-1 levels in animal models. This feature makes CJC-1295 DAC a particularly interesting tool in research on chronic stimulation of the somatotropic axis.

CJC-1295 DAC is not a drug, dietary supplement or medicinal product – it is a substance intended for scientific research purposes only.

CJC-1295 DAC variants available

The product is supplied with a Certificate of Analysis (CoA) with HPLC and MS results. Detailed specifications available on the product page.

Which CJC-1295 DAC variant should you choose?

CJC-1295 DAC is available from One Peptides in the form of a lyophilisate containing 5 mg of substance per vial. Due to the extended half-life of this peptide (days instead of minutes), the substance requirement per experimental time point is lower than in the case of the non-DAC version. The content of 5 mg allows you to conduct both initial pilot experiments and extensive research series with many groups of animals.

When choosing between CJC-1295 DAC and the non-DAC version, consider the research goal – the DAC version generates long-term, continuous stimulation of the somatotropic axis, which makes it a suitable tool for studies on chronic exposure to elevated levels of GH and IGF-1 in animal models.

Please note that once reconstituted, the CJC-1295 DAC solution is stored at 2-8 degrees Celsius. Lyophilisate in its original packaging requires a temperature below -20 degrees Celsius.

How is CJC-1295 DAC different from similar peptides?

CJC-1295 DAC vs CJC-1295 (without DAC)

The main difference between these two variants is pharmacokinetics. CJC-1295 without DAC has a short half-life (minutes) and generates pulsatile GH stimulation – more similar to the natural secretory rhythm. CJC-1295 DAC, thanks to its covalent bond with albumin, maintains elevated GH levels for days. The choice between them depends on whether the research protocol requires acute or chronic stimulation of the somatotropic axis. See category: CJC-1295

CJC-1295 DAC vs Ipamorelin

Ipamorelin is a pentapeptide acting through the ghrelin receptor (GHS-R1a), not the GHRH-R receptor like CJC-1295 DAC. These two peptides engage completely different signaling pathways. The scientific literature describes the parallel use of GHRH analogues with GHS-R agonists in animal models, which led to a synergistic enhancement of the somatotropic response. CJC-1295 DAC and Ipamorelin are therefore complementary, not competitive research tools. See category: Ipamorelin

FAQ – Frequently asked questions

1. What is CJC-1295 DAC and how is it different from CJC-1295?
CJC-1295 DAC is a version of the CJC-1295 peptide conjugated to the DAC (Drug Affinity Complex) module, which binds to plasma albumin. The difference is in pharmacokinetics – the DAC version has a half-life many times longer in the plasma of animal models (days instead of minutes).

2. What is a DAC module?
DAC (Drug Affinity Complex) is a reactive maleimide ester developed by ConjuChem Biotechnologies. After administration, it forms a covalent bond with albumin, which protects the peptide against enzymatic degradation and renal elimination, extending its bioavailability.

3. Is CJC-1295 DAC a drug or dietary supplement?
NO. CJC-1295 DAC offered at One Peptides is a substance intended exclusively for scientific research (Research Use Only). It is not a medicinal product, drug or dietary supplement.

4. How should CJC-1295 DAC be stored?
Store the lyophilisate at a temperature below -20 degrees Celsius in the original packaging. After reconstitution, store the solution at 2–8 degrees Celsius and use within a few days or divide into aliquots and freeze.

5. What signaling pathways does CJC-1295 DAC engage?
CJC-1295 DAC binds to the GHRH-R receptor, activating the cAMP/PKA pathway in pituitary somatotropes. In animal models, this leads to an increase in GH levels and, secondarily, IGF-1 – in a continuous, not pulsatile manner due to the prolonged half-life.

Quality and standards at One Peptides

All peptides in the One Peptides catalogue, including CJC-1295 DAC, are subject to rigorous quality control. Each batch is analyzed by HPLC (High-Performance Liquid Chromatography) to confirm purity and mass spectrometry (MS) to verify molecular identity. Each product is accompanied by a Certificate of Analysis (CoA) and a Safety Data Sheet (SDS). This translates into the repeatability and reliability of research results.